The global Pen Injectors Market is segmented on the basis of design factors, drug classes, therapeutic sector assessment, type, application, usage and region. Pen injectors are mainly used for the subcutaneous delivery of biopharmaceuticals, primarily for self-administration by the patient. The ability to self-inject has been the core driver for their development and made them such an important part of the world of drug delivery devices for more than 25 years. With the world wide increase in diabetes as well as the trend towards biological drugs which cannot be administered orally, pen injectors importance continues to grow. Pens have continuously been developed to meet the needs of patients in the key areas of diabetes (insulin and glucagon-like peptide), growth hormone and other hormone replacement therapies, hepatitis C, multiple sclerosis, cancer treatment, autoimmune diseases, and emergency injections for treating anaphylactic shock and migraine.
Insulin pensare used to inject insulin to treat diabetes and pancreas are normally responsible for its production. It comprises an insulin cartridge (integrated or bought separately) and a separate dial to measure the dose, and is used with disposable pen needles to deliver the dose. A durable pen uses a replaceable insulin cartridge. On the insulin cartridge becoming empty, the empty cartridge can be disposed of and a new one is implanted in the pen. Further, a prefilled pen is disposable entirely. Therefore, the pen comes pre-filled with insulin, and the entire unit is discarded when the insulin cartridge or reservoir gets empty.
On the basis of design factors, the pen injectors market is segmented into Standardized Pen Platforms, Custom Pen Designs, Reusable Pens, Prefilled Pen Cartridges, Disposable Pens, Dual Chamber Pens, Variable vs. Fixed Dosing, and Connected Pens. On the basis of drug classes, the global market is segmented into Antibodies, Anticholinergics, Dopamine Receptors, Hematopoietics, Human Growth Hormone, Immune Modulators, Insulins and Antihyperglycemics, Parathyroid Hormone, Reproductive Hormones, Serotonin Antagonists, and Sympathomimetics.
On the basis of therapeutic assessment, the pen injectors market is classified into Anemial, Inflammatory Autoimmune Diseases, Diabetes, Emergency Medicine, Hepatitis, Hormone Replacement, Osteoporosis, Reproductive Health, and the other Commercial Pen Markets & Products. On the basis of type, Insulin Pen Injector holds the largest market share of the global pen injector market. Insulin pen injector is sub segmented into durable and prefilled.
On the basis of application, the pen injectors market is classified into Hospital, Clinic, and others. On the basis of usage, the global market is classified into reusable pen injector and disposable pen injector.Both the segments account for amajority market share in the global market, with reusable pens enjoying a slightly larger share. It has been noted that disposable pens are preferred in emerging economies such as China and India, while patients in developed countries such as England, Japan, and Germany prefer reusable injection pens.
Geographically, the global market is segmented into North America, Europe, China, Japan, India, and Southeast Asia. North America accounts for the largest market share of pen injector market. Followed by Europe. The U.S. takes the lead of market in North America. This is due to an extensive diabetic population in the country, various technological advancements, surging research and development practices and growing healthcare awareness about the treatment and management of glucose levels.Asia is projected to exhibit strong growth during the forecast period, with major contribution from countries such as India, Japan, and China. New product launches, favorable regulations, the ability of patients to pay for advanced medical products and devices, and growing awareness levels are likely to drive the market.
The key players in the pen injector market include Bayer AG, Sanofi, Amedra Pharmaceuticals, ALK Abello, Novartis International AG, Unilife Corporation, Pfizer, Emerade, Ypsomed Holding AG, Sanofi S. A, Biogen Idec, Inc., Emergent BioSolutions, and Owen Mumford.
This report studies Pen Injectors in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering
• Bayer AG
• Amedra Pharmaceuticals
• ALK Abello
• Novartis International AG
• Unilife Corporation
• Ypsomed Holding AG
• Sanofi S. A
• Biogen Idec, Inc
• Emergent BioSolutions
• Owen Mumford
Market Segment by Regions, this report splits Global into several key Region, with production, consumption, revenue, market share and growth rate of Pen Injectors in these regions, from 2011 to 2021 (forecast), like
• North America
• Southeast Asia
Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into
• Type I
• Type II
• Type III
Split by application, this report focuses on consumption, market share and growth rate of Pen Injectors in each application, can be divided into
• Application 3
Research Support Specialist, USA